🔎 Trials Near Me

Akèy › Myelom Miltip › Florid

Etid klinik pou Myelom Miltip nan Florid

55 etid pou Myelom Miltip ap chèche patisipan nan sit nan Florid.

Vil nan Florid

Tèks ofisyèl etid la (Anglè)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  • Mayo Clinic in Florida, Jacksonville
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06630104

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

  • Moffitt Cancer Center /ID# 279068, Tampa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07409246

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • Memorial Healthcare System, Hollywood
  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando
  • Cleveland Clinic Florida, Weston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Florida Cancer Specialists & Research Institute, Fort Myers
  • Mayo Clinic Jacksonville, Jacksonville
  • Moffit Cancer center, Tampa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Memorial Healthcare System, Hollywood
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04634552

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Jacksonville, Jacksonville
  • Memorial Cancer Institute, Pembroke Pines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

  • Comprehensive Hematology Oncology, St. Petersburg
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07609940

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  • Cancer Specialists of North Florida, Jacksonville
  • D&H National Research Center, Margate
  • Ocala Oncology Center, Ocala
  • ak 2 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07477587

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • University of Miami/Sylvester Cancer Institute - Aventura, Aventura
  • University of Miami/Sylvester Cancer Institute - Lennar, Coral Gables
  • University of Miami/Sylvester Cancer Institute - Deerfield Beach, Deerfield Beach
  • ak 8 plis
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Florida, Jacksonville
  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06465316

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • SSAK Partners, Coral Springs
  • Mayo Clinic - Jacksonville, Jacksonville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

  • University of Miami, Miami
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06997081

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • Baptist MD Anderson Cancer Center, Jacksonville
  • University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Florida, Jacksonville
  • Miami Cancer Institute at Baptist Health, Inc., Miami
  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Florida, Jacksonville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06375044

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07075185

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, Tampa
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

  • GSK Investigational Site, Fort Myers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07227311

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  • Sylvester Comprehensive Cancer Center - Aventura, Aventura
  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables
  • Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
  • ak 6 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05020236

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
  • University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach
  • Sylvester Comprehensive Cancer Center- Doral, Doral
  • ak 12 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  • GSK Investigational Site, Pembroke Pines
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05714839

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Holy Cross Hospital, Fort Lauderdale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  • Mayo Clinic Hospital - Florida, Jacksonville
  • University of Miami Don Soffer Clinical Research Center, Miami
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

  • University of Miami, Miami
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06376526

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Jacksonville
  • Research Site, Miami
  • Research Site, Tampa
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Coral Gables
  • Research Site, Tampa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • University of Florida, Gainesville
  • University of Miami, Miami
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Mayo Clinic - Florida, Jacksonville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

  • Mayo Clinic in Florida, Jacksonville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT05847569

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
  • University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach
  • Sylvester Comprehensive Cancer Center, Miami
  • ak 2 plis
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06057402

Integrated Cancer Repository for Cancer Research

  • Florida Hospital Memorial Medical Center, Daytona Beach
  • Florida Hospital DeLand, DeLand
  • Florida Hospital FISH, Orange City
  • ak 2 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Holy Cross Hospital, Fort Lauderdale
  • Mayo Clinic in Florida, Jacksonville
  • Jupiter Medical Center, Jupiter
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.